MONOPIL

0,15 MG / 0,03 MG · comprime enrobe · box of 63

Historical reference: this presentation is not marketed, withdrawn or suspended according to the source. Its listed price does not establish availability.

Reference dated : 2026-10-01. Confirm price and availability with a pharmacist.

Public price

22,70 MAD

Laboratory

PFIZER

Composition and presentation

MONOPIL — LEVONORGESTREL // ETHINYLESTRADIOL. Listed presentation: 0,15 MG / 0,03 MG · COMPRIME ENROBE · BOITE DE 63.

Full clinical reference

Additional sections are available in French. Read the original document; the information concerns the French reference product.

Uses

Oral hormonal contraception.

The decision to prescribe MINIDRIL must be made taking into account the patient's risk factors, in particular her risk factors for venous thromboembolism (VTE), as well as the risk of VTE associated with MINIDRIL in comparison to other CHCs (Combined Hormonal Contraceptives) (see sections 4.3 and 4.4).

Pregnancy and breastfeeding

Pregnancy

MINIDRIL is not indicated during pregnancy. In case of discovery of a pregnancy while taking this medicine, its use must be immediately discontinued.

Many epidemiological studies have not revealed an increase in the risk of congenital anomalies in children born to women who used an oral contraceptive before pregnancy.

No teratogenic effect has been observed when a combined oral contraceptive was taken by mistake at the beginning of pregnancy.

The increased risk of TEV in the postpartum period must be taken into account when resuming MINIDRIL (see sections 4.2 and 4.4).

Breastfeeding

In case of breastfeeding, the use of this medicine is not recommended due to the passage of estroprogestogens into breast milk.

If the woman wishes to breastfeed, another method of contraception must be offered.

Driving

No study on the ability to drive and use machines has been conducted. No effects on the ability to drive and use machines have been observed in users of CHC.

Adverse effects

The following adverse effects have been observed during treatment with oral estrogen-progestogen contraceptives:

For serious adverse effects, such as venous and arterial thromboembolic events, cervical cancers, breast cancers and malignant hepatic tumours, see section 4.4.

An increase in the risk of arterial and venous thrombotic and thrombo-embolic events, including myocardial infarction, stroke, transient ischaemic attacks, venous thrombosis and pulmonary embolism, has been observed in women using CHCs; this is addressed in more detail in section 4.4.

	Common (≥ 1/100 and < 1/10)	Uncommon (≥ 1/1 000 and < 1/100)	Rare (≥ 1/10 000 and < 1/1 000)	Very rare (< 1/10 000)	Frequency unknown
Benign, malignant and unspecified tumours (including cysts and polyps)				Hepatocellular carcinoma, benign hepatic tumours (for example: focal nodular hyperplasia, hepatic adenoma)
Infections and infestations	Vaginitis including vaginal candidiasis
Immune system disorders			Anaphylactic reactions with very rare cases of urticaria, angioedema, severe circulatory and respiratory disorders	Exacerbation of systemic lupus erythematosus	Worsening of symptoms of hereditary or acquired angioedema
Metabolism and nutrition disorders		Appetite changes (increase or decrease)	Glucose intolerance	Exacerbation of porphyria
Psychiatric disorders	Mood changes including depression, libido changes.
Nervous system disorders	Nervousness, dizziness			Exacerbation of chorea
Eye disorders			Irritation by contact lenses	Optic neuritis
Vascular disorders		Hypertension	Venous thromboembolism and arterial thromboembolism	Worsening of varices
Gastrointestinal disorders	Nausea, vomiting, abdominal pain	Abdominal cramps, bloating		Ischaemic colitis	Inflammatory bowel disease (Crohn's disease, ulcerative colitis)
Hepatobiliary disorders			Cholestatic jaundice	Pancreatitis, biliary lithiasis, cholestasis	Hepatocellular damage (for example: hepatitis, abnormal liver function)
Skin and subcutaneous tissue disorders	Acne	Rashes, chloasma (melasma) with risk of persistence, hirsutism, alopecia	Erythema nodosum	Erythema multiforme
Kidney and urinary tract disorders				Haemolytic uraemic syndrome
Reproductive system and breast disorders	Pain, tenderness, swelling and breast secretions, dysmenorrhoea, changes in menstruation, changes in ectropion and vaginal secretions, amenorrhoea
General disorders and administration site conditions	Fluid retention/oedema Weight changes (increase or decrease)
Investigations		Changes in plasma lipids, including hypertriglyceridemia, increase in blood pressure		Decrease in serum folate levels

Reporting of suspected adverse effects

Reporting suspected adverse effects after medicinal product authorization is important. It allows for continuous monitoring of the benefit/risk ratio of the medicine. Healthcare professionals report any suspected adverse effect via the national reporting system: French National Agency for Medicines and Health Products Safety (ANSM) and the network of Regional Pharmacovigilance Centres - Website: https://signalement.social-sante.gouv.fr/

Read the French reference

Hospital price

14,10 MAD

Commercial status

Retiré du Marché

Therapeutic class

References and update dates

AMMPS — catalogue marocain officiel · 2026-10-01

Product and price reference

This information is informational and must be confirmed by a pharmacist or doctor. Do not change medicine or dosage based only on this page.

Price history

Reference price recorded since 2026-10-01: 22,70 MAD

Reference price recorded since 2026-06-01: 22,70 MAD

Referenced presentations and strengths

MONOPIL

0,15 MG / 0,03 MG · comprime enrobe · box of 21

8,80 MAD

Same ingredient, strength and form

This grouping does not establish interchangeability.

Other strengths and forms

Routes and instructions may differ.

MONOPIL

Composition and presentation

Full clinical reference

Price history

Referenced presentations and strengths

MONOPIL

Same ingredient, strength and form

ANOVEL

MICROGYNON /

MINIDRIL

Other strengths and forms